FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private

BSE2188.0011.95 (+0.55 %)

PREV CLOSE (Rs.) 2176.05

OPEN PRICE (Rs.) 2224.75

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3329

TODAY'S LOW / HIGH (Rs.)2169.00 2224.75

52 WK LOW / HIGH (Rs.)1551.05 2636

NSE2203.9027.7 (+1.27 %)

PREV CLOSE( Rs. ) 2176.20

OPEN PRICE (Rs.) 2175.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 2203.90 (49)

VOLUME 64216

TODAY'S LOW / HIGH(Rs.) 2175.00 2213.50

52 WK LOW / HIGH (Rs.)1599 2641

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

72.84

Dividend Yield(%)

0.27

TTM EPS (Rs.)

46.42

P/E Ratio

47.14

Book Value (Rs.)

232.49

Face Value (Rs.)

MCap (Rs. in Mn)

166313.59

Price/Earning (TTM)

44.05

Price/Sales (TTM)

22.19

Price/Book (MRQ)

9.41

PAT Margin (%)

45.12

ROCE (%)

28.58

Incorporation Year : 1990

Management Info :

C C Paarthipan - Chairman Sridhar Ganesan - Managing Director

Registered Office :

Address : 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,Perungudi,
Chennai,
Tamil Nadu-600096

Phone : 044-24968000 / 8012772888 / 71148000

Email : info@caplinpoint.net

Website : www.caplinpoint.net

Registrars Details :

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)

II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai

Listing : BSE, NSE

NEWS

03Sep Caplin Point’s arm gets USFDA’s final
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been grante..

03Sep Caplin Point Laboratories informs abou
Caplin Point Laboratories has informed that it enclosed a Press Release..

08Aug Caplin Point Laboratories gains on rep
Caplin Point Laboratories is currently trading at Rs 2070.85, up by 13.4..

Financials

	QTR Jun 25	ANNUAL 25
Net Profit	858.9	3394.9
Gross Profit	1124.6	4416.7
Operating Profit	1186.4	4665.6
Net Sales	1825.7	7524.1

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glenmark Pharma (BSE)

2114.00 (2.99%)

M.Cap (Rs. in Cr)59657.25

Astrazeneca Pharma I (BSE)

9085.80 (0.58%)

M.Cap (Rs. in Cr)22714.50

Gland Pharma (BSE)

1913.50 (2.40%)

M.Cap (Rs. in Cr)31526.14

Wockhardt (BSE)

1504.00 (3.04%)

M.Cap (Rs. in Cr)24438.82

Shareholding Pattern

	PROMOTERS	70.56%
	NON-INSTITUTION	21.05%
	MUTUAL FUNDS/UTI	1.93%
	FI/BANKS/INSURANCE	0.22%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Samco Flexi Cap Fun...

6.31

Samco ELSS Tax Save...

2.79

UTI Healthcare Fund...

2.73

UTI Small Cap Fund-Reg(G)

1.53

DSP Nifty Smallcap2...

1.48

Samco Multi Cap Fun...

1.22

ITI Pharma & Health...

1.02

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

CAPLIN POINT LABORATORIES LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives